Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Some statements align with the label excerpt on gradual discontinuation and specific reported symptoms after abrupt/rapid discontinuation (insomnia, nausea, headache, anxiety, hyperhidrosis). However, many other claims are not supported by the provided label excerpts, and the response implies broader withdrawal symptom guidance than what is explicitly supported.
Category Scores
Accurate Statements
Stopping/discontinuing LYRICA should be tapered gradually (not abrupt/rapid) to minimize increased seizure frequency; abrupt or rapid discontinuation may be associated with symptoms including insomnia, nausea, headache, anxiety, hyperhidrosis, and diarrhea.
Label 2.1 (When discontinuing LYRICA, taper gradually over a minimum of 1 week); Label 5.6 (Withdraw gradually to minimize potential of increased seizure frequency; Following abrupt or rapid discontinuation, some patients reported symptoms including insomnia, nausea, headache, anxiety, hyperhidrosis, and diarrhea).
Unsupported Statements
People typically use “coming off Lyrica” to mean tapering off pregabalin to stop it.
Not addressed in the provided label excerpts.
People typically use “coming off Lyrica” to mean switching to a different treatment for the pain condition it was prescribed for.
Not addressed in the provided label excerpts.
Stopping pregabalin suddenly can cause withdrawal symptoms.
The label excerpt supports symptoms after abrupt or rapid discontinuation, but does not use the term 'withdrawal symptoms' nor provide a generalized statement that abrupt cessation 'can cause withdrawal symptoms' as such.
Tapering is usually recommended by clinicians rather than stopping pregabalin at once.
The label states 'taper gradually' but does not support the claim that 'usually recommended by clinicians' vs other practice patterns.
Pregabalin affects the nervous system.
The label excerpt includes a mechanism involving alpha2-delta binding but does not explicitly state 'affects the nervous system' in the provided sections.
When pregabalin is stopped quickly, the body can react with withdrawal symptoms.
Label supports reported symptoms after abrupt/rapid discontinuation, but does not describe them specifically as 'withdrawal symptoms' or 'the body can react with withdrawal symptoms.'
Commonly reported withdrawal symptoms after stopping pregabalin include anxiety.
Label 5.6 lists anxiety among symptoms reported after abrupt/rapid discontinuation, but the excerpt does not state 'commonly' for anxiety.
Commonly reported withdrawal symptoms after stopping pregabalin include insomnia.
Label 5.6 lists insomnia among symptoms after abrupt/rapid discontinuation, but does not state 'commonly.'
Commonly reported withdrawal symptoms after stopping pregabalin include nausea.
Label 5.6 lists nausea among symptoms after abrupt/rapid discontinuation, but does not state 'commonly.'
Commonly reported withdrawal symptoms after stopping pregabalin include sweating.
Label uses 'hyperhidrosis' but does not support 'sweating' as a specifically 'common' symptom wording.
Commonly reported withdrawal symptoms after stopping pregabalin include dizziness.
Dizziness appears as an adverse reaction leading to discontinuation (6.1), but it is not listed among symptoms after abrupt/rapid discontinuation in 5.6.
Commonly reported withdrawal symptoms after stopping pregabalin include headache.
Label 5.6 lists headache among symptoms after abrupt/rapid discontinuation, but does not state 'commonly.'
Commonly reported withdrawal symptoms after stopping pregabalin include return or worsening of the original pain.
Not supported in the provided label excerpts.
Commonly reported withdrawal symptoms after stopping pregabalin include return or worsening of seizure-related symptoms if it was used for that.
Label 5.6 references increased seizure frequency with abrupt/rapid discontinuation in patients with seizure disorders, but does not support 'return or worsening of seizure-related symptoms' as a 'commonly reported withdrawal symptom' in the manner stated.
Tapers of pregabalin vary based on dose.
Not specified in the provided label excerpts (other than minimum 1 week taper when discontinuing).
Tapers of pregabalin vary based on how long the person has been taking it.
Not specified in the provided label excerpts.
Tapers of pregabalin vary based on why the person is taking it (nerve pain, fibromyalgia, etc.).
Not specified in the provided label excerpts.
Clinicians usually reduce the pregabalin dose gradually over weeks to months rather than making a rapid cut.
Label specifies taper gradually over a minimum of 1 week, but does not support 'weeks to months' or 'usually'.
Clinicians aim for a taper that is slow enough to avoid withdrawal.
Label 5.6 focuses on minimizing increased seizure frequency and lists symptoms after abrupt/rapid discontinuation; it does not use 'avoid withdrawal' wording.
Near the end of the pregabalin taper, smaller dose reductions may be used.
Not specified in the provided label excerpts.
A prescriber should set the pregabalin taper schedule, especially if the person has been on it for a long time or at higher doses.
Not specified in the provided label excerpts.
During a pregabalin taper, people may watch for withdrawal-like symptoms including restlessness.
Restlessness is not listed in the provided label excerpts.
During a pregabalin taper, people may watch for withdrawal-like symptoms including flu-like feelings.
Not listed in the provided label excerpts.
During a pregabalin taper, people may watch for nervous system symptoms including dizziness.
Dizziness is mentioned as an adverse reaction leading to discontinuation (6.1), but the label excerpt does not list dizziness among symptoms after discontinuation in 5.6.
During a pregabalin taper, people may watch for nervous system symptoms including headache.
Headache is listed after abrupt/rapid discontinuation in 5.6, but the label excerpt does not state that patients should monitor for it 'during a taper' (as opposed to after abrupt/rapid discontinuation).
During a pregabalin taper, people may watch for symptoms returning including pain, burning/tingling, sleep disruption.
Not supported in the provided label excerpts.
If symptoms spike during a pregabalin taper, prescribers sometimes slow the taper or pause at the last tolerated dose.
Not specified in the provided label excerpts.
If stopping pregabalin due to side effects, the prescriber may consider alternatives for the underlying condition rather than stopping abruptly.
Label 5.6 addresses gradual withdrawal and seizure frequency risk; it does not provide guidance about selecting alternatives or stopping due to side effects.
Higher withdrawal concerns for pregabalin are associated with being on pregabalin for many months or years.
Not specified in the provided label excerpts.
Higher withdrawal concerns for pregabalin are associated with being on a higher daily dose.
Not specified in the provided label excerpts.
Higher withdrawal concerns for pregabalin are associated with using it for seizure-related indications.
Label 5.6 specifically links abrupt/rapid discontinuation to increased seizure frequency in seizure disorders, but does not describe it as 'higher withdrawal concerns' broadly or provide linkage in the way stated.
Withdrawal concerns for pregabalin may be higher if the person takes other medications that affect the nervous system.
Not supported in the provided label excerpts.
Often, a person can switch to another medicine when stopping pregabalin.
Not specified in the provided label excerpts.
The safest pregabalin switch depends on what is being treated (neuropathic pain vs fibromyalgia vs seizures).
Not specified in the provided label excerpts.
A prescriber may start the new therapy while tapering pregabalin to reduce rebound symptoms.
Not specified in the provided label excerpts.
Seek urgent care for severe agitation during pregabalin tapering.
Not specified in the provided label excerpts.
Seek urgent care for confusion during pregabalin tapering.
Not specified in the provided label excerpts.
Seek urgent care for fainting during pregabalin tapering.
Not specified in the provided label excerpts.
Seek urgent care for suicidal thoughts during pregabalin tapering.
Label 5.3 addresses monitoring AEDs for suicidal ideation/behavior, but does not provide 'seek urgent care during pregabalin tapering' guidance in the excerpt.
Seek urgent care for seizures during pregabalin tapering.
Label 5.6 notes increased seizure frequency risk with abrupt/rapid discontinuation, but the excerpt does not provide an instruction to 'seek urgent care' for seizures during tapering.
If tapering pregabalin and worsening quickly, contact the prescribing clinician promptly.
Not specified in the provided label excerpts.
Contradictions
Important Omissions
Discontinuation should be tapered gradually over a minimum of 1 week (explicit label instruction).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response provides several symptom-monitoring and urgency recommendations that are not supported by the provided label excerpts, and it includes multiple withdrawal-related claims beyond what is explicitly listed in the label (5.6). While it does align with the key label concept of gradual tapering and lists some specific post-abrupt-discontinuation symptoms, unsupported expansion could lead to inaccurate expectations or actions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Many claims (e.g., broad 'commonly reported withdrawal symptoms', dose/duration-based taper tailoring, patient urgency guidance) are not supported by the provided label excerpts.
Suggested Improvement
Restrict discontinuation guidance to what is explicitly supported: taper gradually over at least 1 week; note the label-listed symptoms after abrupt/rapid discontinuation (insomnia, nausea, headache, anxiety, hyperhidrosis, diarrhea) and seizure-frequency risk in seizure disorders; avoid adding 'common' frequency, additional unlisted symptoms, and 'seek urgent care' instructions unless present in the provided labeling.